Evogene Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-20upcoming | -0.27 | — | — |
| 2026-05-20 | -0.27 | -0.61 | -125.74% |
| 2026-03-05 | -0.26 | -0.62 | -137.46% |
| 2025-11-20 | -0.41 | -0.46 | -13.39% |
| 2025-08-19 | -0.63 | -0.50 | +20.63% |
| 2025-05-21 | -0.50 | -0.38 | +24.75% |
| 2025-03-06 | -0.72 | 0.06 | +108.28% |
| 2024-11-21 | -1.01 | -1.31 | -29.70% |
| 2024-08-22 | -1.20 | -1.06 | +11.67% |
| 2024-05-23 | -0.90 | -0.80 | +11.11% |
| 2024-03-07 | -1.40 | -1.30 | +7.14% |
| 2023-11-15 | -1.57 | -0.80 | +48.94% |
| 2023-08-17 | -1.75 | -1.70 | +2.86% |
| 2023-05-18 | -1.60 | -1.50 | +6.25% |
| 2023-03-09 | -2.00 | -0.70 | +65.00% |
| 2022-11-17 | -1.97 | -1.60 | +18.64% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| EVGN | -7.79% | -16.47% | -35.45% | -34.86% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -10.76% | -11.83% | -32.01% | -47.55% |